{"result": "(\"entity\"<|>SIADH<|>EVENT<|>SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion) is a condition characterized by excessive release of antidiuretic hormone leading to water retention and hyponatremia.)\n##\n(\"entity\"<|>CONIVAPTÁN<|>ORGANIZATION<|>Conivaptán is a medication used intravenously to treat hyponatremia associated with SIADH, blocking the V2 receptor to promote water excretion.)\n##\n(\"entity\"<|>TOLVAPTÁN<|>ORGANIZATION<|>Tolvaptán is an oral medication approved in Europe for the treatment of hyponatremia associated with SIADH, enhancing renal water excretion.)\n##\n(\"entity\"<|>EUROPA<|>GEO<|>Europe is the continent where tolvaptán is available for treating SIADH-related hyponatremia.)\n##\n(\"entity\"<|>HIPONATREMIA<|>EVENT<|>Hyponatremia is a condition characterized by low sodium levels in the blood, often associated with SIADH.)\n##\n(\"entity\"<|>FUROSEMIDA<|>ORGANIZATION<|>Furosemide is a diuretic medication that can be used in the treatment of various conditions, including fluid retention.)\n##\n(\"entity\"<|>VIH<|>EVENT<|>HIV (Human Immunodeficiency Virus) is a virus that can lead to acquired immunodeficiency syndrome and is mentioned as a potential cause of SIADH.)\n##\n(\"entity\"<|>NEUMONÍA<|>EVENT<|>Pneumonia is an infection that can lead to various complications, including secondary SIADH.)\n##\n(\"relationship\"<|>TOLVAPTÁN<|>SIADH<|>Tolvaptán is indicated for the treatment of hyponatremia associated with SIADH<|>8)\n##\n(\"relationship\"<|>CONIVAPTÁN<|>SIADH<|>Conivaptán is used to treat hyponatremia secondary to SIADH<|>8)\n##\n(\"relationship\"<|>EUROPA<|>TOLVAPTÁN<|>Tolvaptán is available in Europe for treating SIADH-related hyponatremia<|>5)\n##\n(\"relationship\"<|>FUROSEMIDA<|>SIADH<|>Furosemida is mentioned as a treatment option for conditions related to SIADH<|>4)\n##\n(\"relationship\"<|>HIPONATREMIA<|>SIADH<|>Hyponatremia is a common consequence of SIADH<|>9)\n##\n(\"relationship\"<|>VIH<|>SIADH<|>HIV can lead to SIADH as a complication<|>3)\n##\n(\"relationship\"<|>NEUMONÍA<|>SIADH<|>Pneumonia can induce SIADH<|>3)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: de SIADH se prevé limitada (por ejemplo, el SIADH secundario a neumonía)65. En la tabla 5 se muestra la probable duración del tratamiento del SIADH según la etiología y el riesgo relativo de SIADH crónico. Aunque este fármaco tiene también poca evidencia en el tratamiento del SIADH, al menos conocemos bien sus efectos secundarios, al ser de uso frecuente en otras patologías. Entre los efectos secundarios más frecuentes destaca la hipopotasemia, reversible con la suplementación de potasio y tras la retirada de la furosemida.\n\nd. Antagonistas del receptor de vasopresina (vaptanes). Los vaptanes revierten el efecto antidiurético de la ADH, a través del bloqueo competitivo del receptor V2 en el túbulo colector, favoreciendo la eliminación renal de agua libre e incrementándose así la natremia sérica. Tanto el conivaptán (uso intravenoso) como el tolvaptán (uso oral) han demostrado, en ensayos clínicos aleatorizados, seguridad y eficacia en el tratamiento de la hiponatremia secundaria a SIADH y en la hipervolémica64, 78, 79. En Europa solo está disponible el tolvaptán y únicamente está aprobado su uso en hiponatremia asociada a SIADH. Siguiendo las recomendaciones del algorit-\n\n| Tabla 5. Estimación de la duración del tratamiento del SIADH según la etiología y el riesgo relativo de SIADH crónico. Adaptado de Verbalis J. Endocrinol Nutr, 2010. |\n|---|\n\n| Etiología del SIADH | Duración probable del tratamiento | Riesgo relativo de SIADH crónico |\n|---|---|---|\n| Tumor productor de ADH de forma ectópica (oat-cell, etc.) | Determinada por la evolución de la enfermedad subyacente | 1 |\n| Inducido por fármacos, con continuación del uso de este (carbamacepina, etc.) | Duración del tratamiento con el fármaco | 1 |\n| Hemorragia subaracnoidea | 1-4 semanas | 0,8 |\n| Masas cerebrales | Determinada por la evolución de la enfermedad subyacente | 0,8 |\n| Idiopático (senil del anciano) | Indefinido | 0,6 |\n| Accidente cerebrovascular | 1-4 semanas | 0,5 |\n| Insuficiencia respiratoria (EPOC) | Depende de la respuesta a tratamiento | 0,5 |\n| Lesiones cerebrales inflamatorias | Depende de la respuesta a tratamiento | 0,4 |\n| Infección VIH | Depende de la respuesta a tratamiento | 0,2 |\n| Traumatismo craneoencefálico | 2-7 días a indefinido | 0,2 |\n| Inducido por fármacos, con supresión del uso de este (carbamacepina, etc.) | Duración del tratamiento con el fármaco | 0 |\n| Neumonía | 2-5 días | 0 |\n\nADH: hormona antidiurética; EPOC: enfermedad pulmonar obstructiva crónica; SIADH: síndrome de secreción inadecuada de la hormona antidiurética.\n---\nTema 51. Metabolismo hídrico en los pacientes con nutrición artificial... 811\n\nmo multidisciplinar español de manejo de la hipo-\nnatremia secundaria a SIADH, el tolvaptán estaría\nindicado en pacientes: no candidatos al tratamien-\nto con RH y furosemida, en ausencia de respuesta a\ndichos tratamientos y en el SIADH crónico65. Tam-\nbién se ha demostrado seguridad y eficacia del tol-\nvaptán en el tratamiento prolongado de los cua-\ndros crónicos de SIADH80. En estos pacientes el\nriesgo de desarrollo de hipernatremia, si dejan de\nbeber agua, es muy bajo. Debido a que, al bloquear\núnicamente la reabsorción de agua en el túbulo co-\nlector, esta se incrementa de forma significativa en\nlas porciones de la nefrona que más agua reabsor-\nben de forma habitual (el túbulo proximal y el asa\ndescendente de Henle). En definitiva, solo se elimi-\nna agua libre con el tolvaptán si ésta llega al túbulo\ncolector; siendo mayor la acuaresis cuanta más\nagua llegue, así como en las primeras 24 horas tras\nsu comienzo. Por ello, se recomienda al paciente\nbeber agua si desarrolla sed y compensar así la\nacuaresis inicial, evitando un mayor incremento de\nla natremia en esas primeras 24 horas. Hecho im-\nprobable que suceda, si se inicia el tratamiento si-\nguiendo el protocolo recogido en el algoritmo mul\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}